Next generation cell therapies for solid tumors

GigaMune was founded as a spin-out from GigaGen in 2017. We are combining unique insight into T cell responses to tumors with massively parallel T cell receptor (TCR) discovery to develop the next generation of T cell therapies.

Discovery of Anti-Tumor T Cell Receptors

GigaMune’s technology is best-in-class for discovery of anti-tumor T cell receptors. We make millions-diverse libraries of TCRs from natural human repertoires, and then find TCRs that bind and induce cellular activation in response to tumor antigens. We focus specifically on solid tumor indications where the clinical need is highest.

Corporate Headquarters

One Tower Place, Suite 750
South San Francisco, CA  94080

Contact Us